Poster-Disease-modifying Therapy
October 25, 2021
Characteristics and Outcomes By Employment and Education Status for Patients Treated with Peginterferon Beta-1a or Intramuscular Interferon Beta-1a
Background: Although socioeconomic disparities that lead to differences in multiple sclerosis (MS) outcomes have been identified, specific...
Poster-Disease-modifying Therapy
October 25, 2021
Treatment Persistence, Safety, Tolerability, and Effectiveness of Diroximel Fumarate in the Real-World: Design of the Phase 4 ExperienceUS Study
Background: Diroximel fumarate (DRF) is an oral fumarate approved in the United States (US) for relapsing multiple sclerosis (MS). DRF...
Poster-Disease-modifying Therapy
October 25, 2021
Analysis of Health Care Provider Reasons for Switching to Diroximel Fumarate from Other Disease-Modifying Therapies
Background: Switching of disease-modifying therapies (DMTs) for treatment of multiple sclerosis (MS) is driven by many factors that are not...